System Designed to Provide High-Quality Images for Drug Discovery and
Development at More Affordable Price
ALAMEDA, Calif., March 31 /PRNewswire-FirstCall/ -- Xenogen Corporation
(Nasdaq: XGEN) announced today the launch of its IVIS Lumina(TM) Imaging
System, an affordable, value-oriented optical imaging system that provides
quantitative fluorescent and bioluminescent imaging capabilities. The IVIS
Lumina System adds to Xenogen's expanding platform of IVIS systems, including
the IVIS 3D System commercially launched in September 2005.
In line with the U.S. Food and Drug Administration's Critical Path
Initiative, companies and research institutions are focusing on improving
pre-clinical research. Xenogen's sophisticated optical imaging technology is
designed to enable researchers to visualize, track and understand biological
processes in living animals, non-invasively and in real time. The result can
provide more accurate, predictable data that helps to improve the success rate
of drug discovery and development and significantly reduce the cost and time
to market for new therapies. Now this technology is offered at a more
affordable price.
Xenogen's IVIS Lumina System was developed with principal investigator
labs and academic institutions in mind because they require a pre-clinical
imaging system that provides high-quality images at a more affordable price.
In turn, the IVIS Lumina System is designed to provide ease of use,
flexibility and high sensitivity for both in vitro and in vivo fluorescent and
bioluminescent imaging.
"With the IVIS Lumina System, we want to give researchers the opportunity
to purchase an IVIS system designed to generate high-quality data at an
affordable price," said Pamela R. Contag, Ph.D., president of Xenogen
Corporation. "The IVIS Lumina System allows researchers to affordably utilize
Xenogen's advanced technology for drug discovery and development."
While the IVIS Lumina System is ideal for first-time customers, it also
allows companies and research institutions that already own IVIS imaging
systems to purchase additional imaging systems. Without a large expenditure,
Xenogen believes the purchase of these supplemental systems can improve
existing customers' efficiency and productivity.
Xenogen also announced the opening of a Web Store, which current and
interested customers can access through the company's Website,
http://www.xenogen.com. The online store offers Xenogen's Biological Solutions,
including accessories for the company's IVIS imaging systems, software,
training and service plans, reagents and transgenic services.
About Xenogen Corporation
Xenogen Corporation is a leading biotechnology company offering an
integrated suite of optical real-time in vivo imaging and genetic modification
technologies that can help expedite drug discovery and development and
significantly reduce the cost and time to market for new therapies. Xenogen's
VivoVision(TM) Systems non-invasively illuminate and monitor biological
processes within living mammals, at the molecular level, in real time. The
technology provides higher quality in vivo data earlier in the drug discovery
and development process. VivoVision(TM) Solutions improve discovery and
pre-clinical research in multiple therapeutic areas. VivoVision(TM)
Biosciences represents more than 15 years of experience in the creation and
characterization of animal models, including genetic modifications,
comprehensive phenotyping, compound profiling and custom design and production
of light producing cells, microorganisms and animals.
More information is available at http://www.xenogen.com.
NOTE: Xenogen(R), Living Image(R), Lumina(TM), VivoVision(TM) and IVIS(R)
are trademarks of Xenogen Corporation.
Forward-Looking Statements
This press release contains forward-looking statements regarding the
performance, adoption, intended uses and benefits of Xenogen's IVIS Lumina
Imaging System, other imaging products and technologies. These forward-looking
statements are based on Xenogen's current expectations, estimates and
assumptions and are subject to many risks, uncertainties and unknown future
events that could cause actual results to differ materially. Actual
performance, adoption, intended uses and benefits of Xenogen's IVIS Lumina
Imaging System, other imaging products and technologies may differ materially
from those set forth in this release due to the risks and uncertainties
inherent in Xenogen's business, including, without limitation: use and
acceptance of Xenogen's products and technologies by pharmaceutical,
biotechnology, biomedical and chemical companies; Xenogen's ability to
continue to deliver its products on a timely basis; Xenogen's ability to
enforce its intellectual property rights or operate without infringing or
misappropriating the proprietary rights of others; products, services or
technologies introduced by competing companies; and other risk factors set
forth in Xenogen's filings with the Securities and Exchange Commission. For a
discussion of these and other factors that could impact the performance,
adoption, intended uses and benefits of Xenogen's IVIS Lumina Imaging System,
other imaging products and technologies and cause them to differ materially
from those in the forward-looking statements, please refer to Xenogen's recent
filings with the Securities and Exchange Commission, including its most recent
annual report on Form 10-K for the year ended December 31, 2005 filed with the
Securities and Exchange Commission on March 24, 2006. Xenogen is under no
obligation to (and specifically disclaims any such obligation to) update or
alter its forward-looking statements whether as a result of new information,
future events or otherwise.
Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
Pamela R. Contag, Ph.D.
http://profnet.prnewswire.com/ud_public.jsp?userid=513625
David W. Carter
http://profnet.prnewswire.com/ud_public.jsp?userid=513851
SOURCE Xenogen Corporation
 back to top
Related links:
http://www.xenogen.com
CONTACT:
investors, William A. Albright of Xenogen
Corporation, +1-510-291-6100; or media, Kelly McKenna of Manning
Selvage & Lee, +1-415-254-6239, or Kelly.mckenna@mslpr.com, for
Xenogen Corporation
|
